Share on StockTwits

Equities research analysts at Morgan Stanley started coverage on shares of IMS Health Holdings (NYSE:IMS) in a research note issued to investors on Wednesday, ARN reports. The firm set an “equal weight” rating and a $26.00 price target on the stock. Morgan Stanley’s target price suggests a potential upside of 3.13% from the company’s current price.

The analysts wrote, “IMS is an attractive way for investors to participate in the growing healthcare analytics end-market. We see valuation as fair, given our outlook for mid-single-digit top-line growth, modest margin expansion, and strong free cash flow.”

A number of other analysts have also recently weighed in on IMS. Analysts at Leerink Swann initiated coverage on shares of IMS Health Holdings in a research note on Wednesday. They set an “outperform” rating and a $29.00 price target on the stock. Separately, analysts at JPMorgan Chase & Co. initiated coverage on shares of IMS Health Holdings in a research note on Wednesday. They set an “overweight” rating and a $28.00 price target on the stock. Finally, analysts at Barclays initiated coverage on shares of IMS Health Holdings in a research note on Wednesday. They set an “equal weight” rating and a $27.00 price target on the stock. Four analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. IMS Health Holdings currently has an average rating of “Buy” and an average price target of $27.40.

IMS Health Holdings (NYSE:IMS) traded down 1.94% during mid-day trading on Wednesday, hitting $24.72. The stock had a trading volume of 366,178 shares. IMS Health Holdings has a 1-year low of $21.63 and a 1-year high of $25.36. The stock has a 50-day moving average of $23.70 and a 200-day moving average of $23.70. The company has a market cap of $8.205 billion and a P/E ratio of 62.40.

IMS Health Holdings, Inc is a global information and technology services company providing clients in the healthcare industry with comprehensive solutions to measure and improve their performance.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.